# Ultrasound-Guided Regional Anesthesia Using a Mixture of Dexamethasone, Dexmedetomidine, and 0.2% Levobupivacaine for Bilateral Breast Cancer Surgery Under a Spontaneous Breathing Opioid-Free Anesthesia: A Case Report

**Authors:** Fabrizio Falso, Roberto Giurazza, Clotilde Crovella, Rosanna Carmela De Rosa, Antonio Corcione

PMC · DOI: 10.7759/cureus.58394 · 2024-04-16

## TL;DR

A patient underwent breast cancer surgery using a non-opioid anesthesia method involving ultrasound-guided regional anesthesia with a low-dose local anesthetic and adjuvants, providing effective pain relief.

## Contribution

A successful opioid-free anesthesia technique using low-dose levobupivacaine with dexamethasone and dexmedetomidine for bilateral breast cancer surgery is reported.

## Key findings

- The patient experienced effective postoperative analgesia lasting over 48 hours without needing additional opioids.
- The use of adjuvants allowed for a low-dose local anesthetic to be effective in regional anesthesia.
- The method provided successful pain control without general anesthesia.

## Abstract

Breast cancer is unfortunately the most common cancer in women, although survival rates have greatly increased in recent years. Breast surgery can be very aggressive and therefore highly painful, leading to high rates of acute postsurgical pain and chronic pain. In addition to general anesthesia (GA), ultrasound-guided regional anesthesia (RA) is sometimes performed to help reduce acute postoperative pain and consumption of opioids. Although effective, the main limitation of fascial plane blocks is that they require high volumes of local anesthetics, carrying the risk of local anesthetic systemic toxicity. In this article, we present the case of a 41-year-old woman, who refused GA and was successfully operated on for bilateral breast cancer, under a spontaneous breathing opioid-free sedation and ultrasound-guided RA, based on only 0.2% levobupivacaine with the addition of dexamethasone and dexmedetomidine as adjuvants. Despite this, postoperative analgesia lasted for more than 48 hours, and the patient did not require additional analgesia or opioids.

## Linked entities

- **Chemicals:** dexamethasone (PubChem CID 5743), dexmedetomidine (PubChem CID 5311068), levobupivacaine (PubChem CID 92253)
- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Diseases:** chronic pain (MESH:D059350), toxicity (MESH:D064420), Breast Cancer (MESH:D001943), postoperative pain (MESH:D010149), cancer (MESH:D009369)
- **Chemicals:** Dexmedetomidine (MESH:D020927), Levobupivacaine (MESH:D000077554), Dexamethasone (MESH:D003907)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11097996/full.md

---
Source: https://tomesphere.com/paper/PMC11097996